BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30450942)

  • 21. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
    Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
    Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of oral vancomycin prophylaxis for prevention of
    Tariq R; Laguio-Vila M; Tahir MW; Orenstein R; Pardi DS; Khanna S
    Therap Adv Gastroenterol; 2021; 14():1756284821994046. PubMed ID: 33747124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of routine Clostridioides difficile infection (CDI) primary prophylaxis in lung transplant recipients.
    Fitzmaurice MG; Hohlfelder B; Srinivas P; Rudoni M; Brizendine KD; Budev M
    Clin Transplant; 2023 Sep; 37(9):e15079. PubMed ID: 37477286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin Versus Metronidazole for Nonsevere
    Sarna KV; Gross AE
    Ann Pharmacother; 2019 Aug; 53(8):845-852. PubMed ID: 30734567
    [No Abstract]   [Full Text] [Related]  

  • 26. Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.
    van Opstal E; Kolling GL; Moore JH; Coquery CM; Wade NS; Loo WM; Bolick DT; Shin JH; Erickson LD; Warren CA
    J Infect Dis; 2016 Jul; 214(1):130-9. PubMed ID: 26917573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of
    Maraolo AE; Mazzitelli M; Zappulo E; Scotto R; Granata G; Andini R; Durante-Mangoni E; Petrosillo N; Gentile I
    Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Preoperative Oral Antibiotics and the Incidence of Postoperative Clostridium difficile Infection in Adults Undergoing Elective Colorectal Resection: A Systematic Review and Meta-analysis.
    Khorasani S; Dossa F; McKechnie T; Englesakis M; Brar MS; de Buck van Overstraeten A
    Dis Colon Rectum; 2020 Apr; 63(4):545-561. PubMed ID: 32101994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
    Kimura T; Snijder R; Sugitani T
    J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infection.
    Bublitz A; Brauer M; Wagner S; Hofer W; Müsken M; Deschner F; Lesker TR; Neumann-Schaal M; Paul LS; Nübel U; Bartel J; Kany AM; Zühlke D; Bernecker S; Jansen R; Sievers S; Riedel K; Herrmann J; Müller R; Fuchs TM; Strowig T
    Cell Host Microbe; 2023 May; 31(5):734-750.e8. PubMed ID: 37098342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.
    Gebhart D; Lok S; Clare S; Tomas M; Stares M; Scholl D; Donskey CJ; Lawley TD; Govoni GR
    mBio; 2015 Mar; 6(2):. PubMed ID: 25805733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
    Vickers RJ; Tillotson GS; Nathan R; Hazan S; Pullman J; Lucasti C; Deck K; Yacyshyn B; Maliakkal B; Pesant Y; Tejura B; Roblin D; Gerding DN; Wilcox MH;
    Lancet Infect Dis; 2017 Jul; 17(7):735-744. PubMed ID: 28461207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
    Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
    Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical Care Management of the Patient with Clostridioides difficile.
    Adelman MW; Woodworth MH; Shaffer VO; Martin GS; Kraft CS
    Crit Care Med; 2021 Jan; 49(1):127-139. PubMed ID: 33156122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment.
    Li Y; Figler RA; Kolling G; Bracken TC; Rieger J; Stevenson RW; Linden J; Guerrant RL; Warren CA
    BMC Infect Dis; 2012 Dec; 12():342. PubMed ID: 23217055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.
    Stevens VW; Khader K; Echevarria K; Nelson RE; Zhang Y; Jones M; Timbrook TT; Samore MH; Rubin MA
    Clin Infect Dis; 2020 Jul; 71(3):645-651. PubMed ID: 31504328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Vancomycin Prophylaxis for Clostridioides difficile in High-Risk Patients Receiving Systemic Antibiotics: What Exactly Are We Preventing?
    McCreery R; Cawcutt K; Cortes-Penfield N; Van Schooneveld T
    Clin Infect Dis; 2020 Oct; 71(7):1798. PubMed ID: 32052036
    [No Abstract]   [Full Text] [Related]  

  • 39. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.
    Wang J; Ghali S; Xu C; Mussatto CC; Ortiz C; Lee EC; Tran DH; Jacobs JP; Lagishetty V; Faull KF; Moller T; Rossetti M; Chen X; Koon HW
    Gastroenterology; 2018 May; 154(6):1737-1750. PubMed ID: 29360463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.